Pharma & Healthcare
Global Injectable HIV Medication Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 553954
- Pages: 122
- Figures: 117
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Injectable HIV Medication market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
ViiV Healthcare
Janssen Pharmaceuticals
Gilead Sciences
Theratechnologies
Segment by Type
NNRTIs
Capsid Inhibitors
Integrase Inhibitors
Monoclonal Antibodies
Other
Segment by Application
Pre-Exposure Prophylaxis
HIV Treatment
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Injectable HIV Medication study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Injectable HIV Medication market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
ViiV Healthcare
Janssen Pharmaceuticals
Gilead Sciences
Theratechnologies
Segment by Type
NNRTIs
Capsid Inhibitors
Integrase Inhibitors
Monoclonal Antibodies
Other
Segment by Application
Pre-Exposure Prophylaxis
HIV Treatment
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Injectable HIV Medication study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Injectable HIV Medication: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Injectable HIV Medication Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 NNRTIs
1.2.3 Capsid Inhibitors
1.2.4 Integrase Inhibitors
1.2.5 Monoclonal Antibodies
1.2.6 Other
1.3 Market Segmentation by Application
1.3.1 Global Injectable HIV Medication Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pre-Exposure Prophylaxis
1.3.3 HIV Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Injectable HIV Medication Revenue Estimates and Forecasts 2020-2031
2.2 Global Injectable HIV Medication Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Injectable HIV Medication Sales Estimates and Forecasts 2020-2031
2.4 Global Injectable HIV Medication Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Injectable HIV Medication Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Injectable HIV Medication Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 NNRTIs Market Size by Manufacturers
3.5.2 Capsid Inhibitors Market Size by Manufacturers
3.5.3 Integrase Inhibitors Market Size by Manufacturers
3.5.4 Monoclonal Antibodies Market Size by Manufacturers
3.5.5 Other Market Size by Manufacturers
3.6 Global Injectable HIV Medication Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Injectable HIV Medication Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Injectable HIV Medication Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Injectable HIV Medication Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Injectable HIV Medication Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Injectable HIV Medication Sales and Revenue by Type (2020-2031)
6.4 North America Injectable HIV Medication Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Injectable HIV Medication Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Injectable HIV Medication Sales and Revenue by Type (2020-2031)
7.4 Europe Injectable HIV Medication Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Injectable HIV Medication Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Injectable HIV Medication Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Injectable HIV Medication Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Injectable HIV Medication Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Injectable HIV Medication Sales and Revenue by Type (2020-2031)
9.4 Central and South America Injectable HIV Medication Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Injectable HIV Medication Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Injectable HIV Medication Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Injectable HIV Medication Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Injectable HIV Medication Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Corporation Information
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Injectable HIV Medication Product Models, Descriptions and Specifications
11.1.4 ViiV Healthcare Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 ViiV Healthcare Injectable HIV Medication Sales by Product in 2024
11.1.6 ViiV Healthcare Injectable HIV Medication Sales by Application in 2024
11.1.7 ViiV Healthcare Injectable HIV Medication Sales by Geographic Area in 2024
11.1.8 ViiV Healthcare Injectable HIV Medication SWOT Analysis
11.1.9 ViiV Healthcare Recent Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Corporation Information
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals Injectable HIV Medication Product Models, Descriptions and Specifications
11.2.4 Janssen Pharmaceuticals Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Pharmaceuticals Injectable HIV Medication Sales by Product in 2024
11.2.6 Janssen Pharmaceuticals Injectable HIV Medication Sales by Application in 2024
11.2.7 Janssen Pharmaceuticals Injectable HIV Medication Sales by Geographic Area in 2024
11.2.8 Janssen Pharmaceuticals Injectable HIV Medication SWOT Analysis
11.2.9 Janssen Pharmaceuticals Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Injectable HIV Medication Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Injectable HIV Medication Sales by Product in 2024
11.3.6 Gilead Sciences Injectable HIV Medication Sales by Application in 2024
11.3.7 Gilead Sciences Injectable HIV Medication Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Injectable HIV Medication SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Theratechnologies
11.4.1 Theratechnologies Corporation Information
11.4.2 Theratechnologies Business Overview
11.4.3 Theratechnologies Injectable HIV Medication Product Models, Descriptions and Specifications
11.4.4 Theratechnologies Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Theratechnologies Injectable HIV Medication Sales by Product in 2024
11.4.6 Theratechnologies Injectable HIV Medication Sales by Application in 2024
11.4.7 Theratechnologies Injectable HIV Medication Sales by Geographic Area in 2024
11.4.8 Theratechnologies Injectable HIV Medication SWOT Analysis
11.4.9 Theratechnologies Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Injectable HIV Medication Industry Chain
12.2 Injectable HIV Medication Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Injectable HIV Medication Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Injectable HIV Medication Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Injectable HIV Medication Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Injectable HIV Medication Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Injectable HIV Medication: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Injectable HIV Medication Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 NNRTIs
1.2.3 Capsid Inhibitors
1.2.4 Integrase Inhibitors
1.2.5 Monoclonal Antibodies
1.2.6 Other
1.3 Market Segmentation by Application
1.3.1 Global Injectable HIV Medication Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pre-Exposure Prophylaxis
1.3.3 HIV Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Injectable HIV Medication Revenue Estimates and Forecasts 2020-2031
2.2 Global Injectable HIV Medication Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Injectable HIV Medication Sales Estimates and Forecasts 2020-2031
2.4 Global Injectable HIV Medication Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Injectable HIV Medication Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Injectable HIV Medication Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 NNRTIs Market Size by Manufacturers
3.5.2 Capsid Inhibitors Market Size by Manufacturers
3.5.3 Integrase Inhibitors Market Size by Manufacturers
3.5.4 Monoclonal Antibodies Market Size by Manufacturers
3.5.5 Other Market Size by Manufacturers
3.6 Global Injectable HIV Medication Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Injectable HIV Medication Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Injectable HIV Medication Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Injectable HIV Medication Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Injectable HIV Medication Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Injectable HIV Medication Sales and Revenue by Type (2020-2031)
6.4 North America Injectable HIV Medication Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Injectable HIV Medication Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Injectable HIV Medication Sales and Revenue by Type (2020-2031)
7.4 Europe Injectable HIV Medication Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Injectable HIV Medication Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Injectable HIV Medication Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Injectable HIV Medication Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Injectable HIV Medication Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Injectable HIV Medication Sales and Revenue by Type (2020-2031)
9.4 Central and South America Injectable HIV Medication Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Injectable HIV Medication Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Injectable HIV Medication Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Injectable HIV Medication Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Injectable HIV Medication Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Corporation Information
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Injectable HIV Medication Product Models, Descriptions and Specifications
11.1.4 ViiV Healthcare Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 ViiV Healthcare Injectable HIV Medication Sales by Product in 2024
11.1.6 ViiV Healthcare Injectable HIV Medication Sales by Application in 2024
11.1.7 ViiV Healthcare Injectable HIV Medication Sales by Geographic Area in 2024
11.1.8 ViiV Healthcare Injectable HIV Medication SWOT Analysis
11.1.9 ViiV Healthcare Recent Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Corporation Information
11.2.2 Janssen Pharmaceuticals Business Overview
11.2.3 Janssen Pharmaceuticals Injectable HIV Medication Product Models, Descriptions and Specifications
11.2.4 Janssen Pharmaceuticals Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Janssen Pharmaceuticals Injectable HIV Medication Sales by Product in 2024
11.2.6 Janssen Pharmaceuticals Injectable HIV Medication Sales by Application in 2024
11.2.7 Janssen Pharmaceuticals Injectable HIV Medication Sales by Geographic Area in 2024
11.2.8 Janssen Pharmaceuticals Injectable HIV Medication SWOT Analysis
11.2.9 Janssen Pharmaceuticals Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Corporation Information
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Injectable HIV Medication Product Models, Descriptions and Specifications
11.3.4 Gilead Sciences Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Gilead Sciences Injectable HIV Medication Sales by Product in 2024
11.3.6 Gilead Sciences Injectable HIV Medication Sales by Application in 2024
11.3.7 Gilead Sciences Injectable HIV Medication Sales by Geographic Area in 2024
11.3.8 Gilead Sciences Injectable HIV Medication SWOT Analysis
11.3.9 Gilead Sciences Recent Developments
11.4 Theratechnologies
11.4.1 Theratechnologies Corporation Information
11.4.2 Theratechnologies Business Overview
11.4.3 Theratechnologies Injectable HIV Medication Product Models, Descriptions and Specifications
11.4.4 Theratechnologies Injectable HIV Medication Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Theratechnologies Injectable HIV Medication Sales by Product in 2024
11.4.6 Theratechnologies Injectable HIV Medication Sales by Application in 2024
11.4.7 Theratechnologies Injectable HIV Medication Sales by Geographic Area in 2024
11.4.8 Theratechnologies Injectable HIV Medication SWOT Analysis
11.4.9 Theratechnologies Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Injectable HIV Medication Industry Chain
12.2 Injectable HIV Medication Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Injectable HIV Medication Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Injectable HIV Medication Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Injectable HIV Medication Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Injectable HIV Medication Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Injectable HIV Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Injectable HIV Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Injectable HIV Medication Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Injectable HIV Medication Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Injectable HIV Medication Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Injectable HIV Medication Sales by Region (2020-2025) & (K Units)
Table 8. Global Injectable HIV Medication Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Injectable HIV Medication Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Injectable HIV Medication Sales Share by Manufacturers (2020-2025)
Table 12. Global Injectable HIV Medication Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Injectable HIV Medication Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Injectable HIV Medication by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Injectable HIV Medication as of 2024)
Table 16. Global Injectable HIV Medication Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Injectable HIV Medication Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Injectable HIV Medication Manufacturing Base and Headquarters
Table 19. Global Injectable HIV Medication Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Injectable HIV Medication Sales by Type (2020-2025) & (K Units)
Table 23. Global Injectable HIV Medication Sales by Type (2026-2031) & (K Units)
Table 24. Global Injectable HIV Medication Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Injectable HIV Medication Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Injectable HIV Medication ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Injectable HIV Medication Sales by Application (2020-2025) & (K Units)
Table 29. Global Injectable HIV Medication Sales by Application (2026-2031) & (K Units)
Table 30. Injectable HIV Medication High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Injectable HIV Medication Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Injectable HIV Medication Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Injectable HIV Medication ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Injectable HIV Medication Growth Accelerators and Market Barriers
Table 37. North America Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Injectable HIV Medication Growth Accelerators and Market Barriers
Table 40. Europe Injectable HIV Medication Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Injectable HIV Medication Growth Accelerators and Market Barriers
Table 45. Southeast Asia Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Injectable HIV Medication Investment Opportunities and Key Challenges
Table 47. Central and South America Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Injectable HIV Medication Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. ViiV Healthcare Corporation Information
Table 51. ViiV Healthcare Description and Major Businesses
Table 52. ViiV Healthcare Product Models, Descriptions and Specifications
Table 53. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 55. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 56. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 57. ViiV Healthcare Injectable HIV Medication SWOT Analysis
Table 58. ViiV Healthcare Recent Developments
Table 59. Janssen Pharmaceuticals Corporation Information
Table 60. Janssen Pharmaceuticals Description and Major Businesses
Table 61. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Pharmaceuticals Injectable HIV Medication SWOT Analysis
Table 67. Janssen Pharmaceuticals Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Injectable HIV Medication SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Theratechnologies Corporation Information
Table 78. Theratechnologies Description and Major Businesses
Table 79. Theratechnologies Product Models, Descriptions and Specifications
Table 80. Theratechnologies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Theratechnologies Sales Value Proportion by Product in 2024
Table 82. Theratechnologies Sales Value Proportion by Application in 2024
Table 83. Theratechnologies Sales Value Proportion by Geographic Area in 2024
Table 84. Theratechnologies Injectable HIV Medication SWOT Analysis
Table 85. Theratechnologies Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Injectable HIV Medication Product Picture
Figure 2. Global Injectable HIV Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. NNRTIs Product Picture
Figure 4. Capsid Inhibitors Product Picture
Figure 5. Integrase Inhibitors Product Picture
Figure 6. Monoclonal Antibodies Product Picture
Figure 7. Other Product Picture
Figure 8. Global Injectable HIV Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Pre-Exposure Prophylaxis
Figure 10. HIV Treatment
Figure 11. Injectable HIV Medication Report Years Considered
Figure 12. Global Injectable HIV Medication Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 14. Global Injectable HIV Medication Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Injectable HIV Medication Revenue Market Share by Region (2020-2031)
Figure 16. Global Injectable HIV Medication Sales (2020-2031) & (K Units)
Figure 17. Global Injectable HIV Medication Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Injectable HIV Medication Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Injectable HIV Medication Sales Volume Market Share in 2024
Figure 20. Global Injectable HIV Medication Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. NNRTIs Revenue Market Share by Manufacturer in 2024
Figure 23. Capsid Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 24. Integrase Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 25. Monoclonal Antibodies Revenue Market Share by Manufacturer in 2024
Figure 26. Other Revenue Market Share by Manufacturer in 2024
Figure 27. Global Injectable HIV Medication Sales Market Share by Type (2020-2031)
Figure 28. Global Injectable HIV Medication Revenue Market Share by Type (2020-2031)
Figure 29. Global Injectable HIV Medication Sales Market Share by Application (2020-2031)
Figure 30. Global Injectable HIV Medication Revenue Market Share by Application (2020-2031)
Figure 31. North America Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 32. North America Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 34. North America Injectable HIV Medication Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 39. Canada Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 41. Europe Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 42. Europe Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 44. Europe Injectable HIV Medication Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 49. France Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 51. Italy Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 52. Russia Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific Injectable HIV Medication Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 61. Japan Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 64. India Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America Injectable HIV Medication Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa Injectable HIV Medication Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 85. Injectable HIV Medication Industry Chain Mapping
Figure 86. Regional Injectable HIV Medication Manufacturing Base Distribution (%)
Figure 87. Global Injectable HIV Medication Production Market Share by Region (2020-2031)
Figure 88. Injectable HIV Medication Production Process
Figure 89. Regional Injectable HIV Medication Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
Table 1. Global Injectable HIV Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Injectable HIV Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Injectable HIV Medication Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Injectable HIV Medication Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Injectable HIV Medication Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Injectable HIV Medication Sales by Region (2020-2025) & (K Units)
Table 8. Global Injectable HIV Medication Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Injectable HIV Medication Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Injectable HIV Medication Sales Share by Manufacturers (2020-2025)
Table 12. Global Injectable HIV Medication Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Injectable HIV Medication Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Injectable HIV Medication by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Injectable HIV Medication as of 2024)
Table 16. Global Injectable HIV Medication Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Injectable HIV Medication Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Injectable HIV Medication Manufacturing Base and Headquarters
Table 19. Global Injectable HIV Medication Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Injectable HIV Medication Sales by Type (2020-2025) & (K Units)
Table 23. Global Injectable HIV Medication Sales by Type (2026-2031) & (K Units)
Table 24. Global Injectable HIV Medication Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Injectable HIV Medication Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Injectable HIV Medication ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Injectable HIV Medication Sales by Application (2020-2025) & (K Units)
Table 29. Global Injectable HIV Medication Sales by Application (2026-2031) & (K Units)
Table 30. Injectable HIV Medication High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Injectable HIV Medication Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Injectable HIV Medication Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Injectable HIV Medication ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Injectable HIV Medication Growth Accelerators and Market Barriers
Table 37. North America Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Injectable HIV Medication Growth Accelerators and Market Barriers
Table 40. Europe Injectable HIV Medication Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Injectable HIV Medication Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Injectable HIV Medication Growth Accelerators and Market Barriers
Table 45. Southeast Asia Injectable HIV Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Injectable HIV Medication Investment Opportunities and Key Challenges
Table 47. Central and South America Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Injectable HIV Medication Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Injectable HIV Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. ViiV Healthcare Corporation Information
Table 51. ViiV Healthcare Description and Major Businesses
Table 52. ViiV Healthcare Product Models, Descriptions and Specifications
Table 53. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 55. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 56. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 57. ViiV Healthcare Injectable HIV Medication SWOT Analysis
Table 58. ViiV Healthcare Recent Developments
Table 59. Janssen Pharmaceuticals Corporation Information
Table 60. Janssen Pharmaceuticals Description and Major Businesses
Table 61. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Janssen Pharmaceuticals Injectable HIV Medication SWOT Analysis
Table 67. Janssen Pharmaceuticals Recent Developments
Table 68. Gilead Sciences Corporation Information
Table 69. Gilead Sciences Description and Major Businesses
Table 70. Gilead Sciences Product Models, Descriptions and Specifications
Table 71. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Gilead Sciences Sales Value Proportion by Product in 2024
Table 73. Gilead Sciences Sales Value Proportion by Application in 2024
Table 74. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 75. Gilead Sciences Injectable HIV Medication SWOT Analysis
Table 76. Gilead Sciences Recent Developments
Table 77. Theratechnologies Corporation Information
Table 78. Theratechnologies Description and Major Businesses
Table 79. Theratechnologies Product Models, Descriptions and Specifications
Table 80. Theratechnologies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Theratechnologies Sales Value Proportion by Product in 2024
Table 82. Theratechnologies Sales Value Proportion by Application in 2024
Table 83. Theratechnologies Sales Value Proportion by Geographic Area in 2024
Table 84. Theratechnologies Injectable HIV Medication SWOT Analysis
Table 85. Theratechnologies Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Injectable HIV Medication Product Picture
Figure 2. Global Injectable HIV Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. NNRTIs Product Picture
Figure 4. Capsid Inhibitors Product Picture
Figure 5. Integrase Inhibitors Product Picture
Figure 6. Monoclonal Antibodies Product Picture
Figure 7. Other Product Picture
Figure 8. Global Injectable HIV Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Pre-Exposure Prophylaxis
Figure 10. HIV Treatment
Figure 11. Injectable HIV Medication Report Years Considered
Figure 12. Global Injectable HIV Medication Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 14. Global Injectable HIV Medication Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Injectable HIV Medication Revenue Market Share by Region (2020-2031)
Figure 16. Global Injectable HIV Medication Sales (2020-2031) & (K Units)
Figure 17. Global Injectable HIV Medication Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Injectable HIV Medication Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Injectable HIV Medication Sales Volume Market Share in 2024
Figure 20. Global Injectable HIV Medication Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. NNRTIs Revenue Market Share by Manufacturer in 2024
Figure 23. Capsid Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 24. Integrase Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 25. Monoclonal Antibodies Revenue Market Share by Manufacturer in 2024
Figure 26. Other Revenue Market Share by Manufacturer in 2024
Figure 27. Global Injectable HIV Medication Sales Market Share by Type (2020-2031)
Figure 28. Global Injectable HIV Medication Revenue Market Share by Type (2020-2031)
Figure 29. Global Injectable HIV Medication Sales Market Share by Application (2020-2031)
Figure 30. Global Injectable HIV Medication Revenue Market Share by Application (2020-2031)
Figure 31. North America Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 32. North America Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 33. North America Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 34. North America Injectable HIV Medication Sales Volume (K Units) by Type (2020- 2031)
Figure 35. North America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 36. North America Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 37. North America Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 38. US Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 39. Canada Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 40. Mexico Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 41. Europe Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 42. Europe Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Europe Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 44. Europe Injectable HIV Medication Sales Volume (K Units) by Type (2020-2031)
Figure 45. Europe Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 46. Europe Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 47. Europe Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 48. Germany Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 49. France Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 50. U.K. Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 51. Italy Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 52. Russia Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 54. Asia-Pacific Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Asia-Pacific Top 8 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 56. Asia-Pacific Injectable HIV Medication Sales Volume (K Units) by Type (2020- 2031)
Figure 57. Asia-Pacific Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 58. Asia-Pacific Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 59. Asia-Pacific Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Indonesia Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 61. Japan Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 62. South Korea Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 63. China Taiwan Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 64. India Injectable HIV Medication Revenue (2020-2031) & (US$ Million)
Figure 65. Central and South America Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 66. Central and South America Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Central and South America Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 68. Central and South America Injectable HIV Medication Sales Volume (K Units) by Type (2021-2031)
Figure 69. Central and South America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 70. Central and South America Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 71. Central and South America Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Brazil Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 73. Argentina Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 74. Middle East, and Africa Injectable HIV Medication Sales YoY (2020-2031) & (K Units)
Figure 75. Middle East and Africa Injectable HIV Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 76. Middle East and Africa Top 5 Manufacturers Injectable HIV Medication Sales Revenue (US$ Million) in 2024
Figure 77. Middle East and Africa Injectable HIV Medication Sales Volume (K Units) by Type (2021-2031)
Figure 78. South America Injectable HIV Medication Sales Revenue (US$ Million) by Type (2020-2031)
Figure 79. Middle East and Africa Injectable HIV Medication Sales Volume (K Units) by Application (2020-2031)
Figure 80. Middle East and Africa Injectable HIV Medication Sales Revenue (US$ Million) by Application (2020-2031)
Figure 81. GCC Countries Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 82. Turkey Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 83. Egypt Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 84. South Africa Injectable HIV Medication Revenue (2020-2025) & (US$ Million)
Figure 85. Injectable HIV Medication Industry Chain Mapping
Figure 86. Regional Injectable HIV Medication Manufacturing Base Distribution (%)
Figure 87. Global Injectable HIV Medication Production Market Share by Region (2020-2031)
Figure 88. Injectable HIV Medication Production Process
Figure 89. Regional Injectable HIV Medication Production Cost Structure
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232